Dr. Chamie on durability of UGN-101 in low-grade UTUC

“The reason that [long-term follow up is] important is because if you look at the best of hands, the incidence of recurrence of upper tract urothelial carcinoma, even for low and intermediate risk, is still very high,” says Karim Chamie, MD.

In this video, Karim Chamie, MD, discusses the background of the study, “Long-term recurrence free survival following UGN-101 treatment for low-grade upper tract urothelial carcinoma,” presented at the 2021 American Urological Association Annual Meeting, and how it builds on previous studies. Chamie is an associate professor of urology and director of the Urologic Oncology Fellowship at the University of California, Los Angeles.

Related Videos
Matthew J. Ziegelmann, MD, answers a question during a Zoom video interview
Dr. Smita De in an interview with Urology Times
Doctor receiving patient in office | Image Credit © Africa Studio - stock.adobe.com
Alisa J. Stephens-Shields, PhD, answers a question during a Zoom video interview
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Dr. David Sheyn in an interview with Urology Times
Avinash Maganty, MD, answers a question during a Zoom video interview
Rachel Pope, MD, MPH, answers a question during a Zoom interview
Dr. David Canes in an interview with Urology Times
Related Content
© 2023 MJH Life Sciences

All rights reserved.